Shu-Biao Ye1,2, Yi-Kan Cheng3, Jian-Cong Hu1,2, Feng Gao1,2, Ping Lan1,2. 1. Department of Colorectal Surgery, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou 510655, China. 2. Guangdong Institute of Gastroenterology, Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, Guangzhou 510655, China. 3. Department of Radiation Oncology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou 510655, China.
Abstract
BACKGROUND: Metastatic colorectal cancer (mCRC) is a heterogeneous disease. Predictive biomarkers are in great demand to optimize patient selection at high risk for death and to provide a novel insight into potential targeted therapy. METHODS: The present study retrospectively analyzed the gene expression profiles of tumor tissue samples from 4 public CRC cohorts, including 1 RNA-Seq data set from The Cancer Genome Atlas (TCGA) CRC cohort and 3 microarray data sets from GEO. Prognostic analysis was performed to test the predictive value of prognostic gene signature. RESULTS: Of 192 patients, 108 patients (56.3%) were men and median age was 65 years. A prognostic gene signature that consisted of 15 unique genes was generated in the discovery cohort. In the meta-validation cohorts, the signature significantly classified patients into high-risk and low-risk groups with regard to overall survival (OS) in mCRC patients with advanced stage disease and remained as an independent prognostic marker in multivariable analysis (1.57; 95% CI: 1.16-2.11; P=0.003) after adjusting for clinical parameters and molecular types. Gene Set Enrichment Analysis showed that several biological processes, including angiogenesis (P<0.001), epithelial mesenchymal transit (P<0.001) and inflammatory response (P=0.001), were enriched among this prognostic gene signature. CONCLUSIONS: The proposed prognostic gene signature is a promising prognostic tool to estimate OS in mCRC. Prospective larger studies to examine the clinical utility of the biomarkers to guide individualized treatment of mCRC are warranted. 2020 Annals of Translational Medicine. All rights reserved.
BACKGROUND: Metastatic colorectal cancer (mCRC) is a heterogeneous disease. Predictive biomarkers are in great demand to optimize patient selection at high risk for death and to provide a novel insight into potential targeted therapy. METHODS: The present study retrospectively analyzed the gene expression profiles of tumor tissue samples from 4 public CRC cohorts, including 1 RNA-Seq data set from The Cancer Genome Atlas (TCGA) CRC cohort and 3 microarray data sets from GEO. Prognostic analysis was performed to test the predictive value of prognostic gene signature. RESULTS: Of 192 patients, 108 patients (56.3%) were men and median age was 65 years. A prognostic gene signature that consisted of 15 unique genes was generated in the discovery cohort. In the meta-validation cohorts, the signature significantly classified patients into high-risk and low-risk groups with regard to overall survival (OS) in mCRC patients with advanced stage disease and remained as an independent prognostic marker in multivariable analysis (1.57; 95% CI: 1.16-2.11; P=0.003) after adjusting for clinical parameters and molecular types. Gene Set Enrichment Analysis showed that several biological processes, including angiogenesis (P<0.001), epithelial mesenchymal transit (P<0.001) and inflammatory response (P=0.001), were enriched among this prognostic gene signature. CONCLUSIONS: The proposed prognostic gene signature is a promising prognostic tool to estimate OS in mCRC. Prospective larger studies to examine the clinical utility of the biomarkers to guide individualized treatment of mCRC are warranted. 2020 Annals of Translational Medicine. All rights reserved.
Entities:
Keywords:
Metastatic colorectal cancer (mCRC); TCGA; gene signature; prognostic
Authors: David Cunningham; Istvan Lang; Eugenio Marcuello; Vito Lorusso; Janja Ocvirk; Dong Bok Shin; Derek Jonker; Stuart Osborne; Niko Andre; Daniel Waterkamp; Mark P Saunders Journal: Lancet Oncol Date: 2013-09-10 Impact factor: 41.316
Authors: Maria Rosaria Galdiero; Paolo Bianchi; Fabio Grizzi; Giuseppe Di Caro; Gianluca Basso; Andrea Ponzetta; Eduardo Bonavita; Marialuisa Barbagallo; Silvia Tartari; Nadia Polentarutti; Alberto Malesci; Gianni Marone; Massimo Roncalli; Luigi Laghi; Cecilia Garlanda; Alberto Mantovani; Sébastien Jaillon Journal: Int J Cancer Date: 2016-03-24 Impact factor: 7.396
Authors: J K Mooi; P Wirapati; R Asher; C K Lee; P Savas; T J Price; A Townsend; J Hardingham; D Buchanan; D Williams; S Tejpar; J M Mariadason; N C Tebbutt Journal: Ann Oncol Date: 2018-11-01 Impact factor: 32.976
Authors: Giuseppe Di Caro; Michele Carvello; Samantha Pesce; Marco Erreni; Federica Marchesi; Jelena Todoric; Matteo Sacchi; Marco Montorsi; Paola Allavena; Antonino Spinelli Journal: PLoS One Date: 2016-05-26 Impact factor: 3.240
Authors: V De Simone; E Franzè; G Ronchetti; A Colantoni; M C Fantini; D Di Fusco; G S Sica; P Sileri; T T MacDonald; F Pallone; G Monteleone; C Stolfi Journal: Oncogene Date: 2014-09-01 Impact factor: 9.867